Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma
Status:
Not yet recruiting
Trial end date:
2031-09-30
Target enrollment:
Participant gender:
Summary
This phase II clinical trial studies the combination of mosunetuzumab and polatuzumab vedotin
in order to see how well it works in patients with untreated follicular lymphoma.
Mosunetuzumab is an antibody that has been engineered to attach to two target cells in the
immune system: T cells that normally perform tasks like killing virus-infected cells, and
cancerous B cells. Mosunetuzumab has been designed to direct these T cells to kill the
cancerous B cells instead. Polatuzumab vedotin is an antibody-drug conjugate that attaches to
certain cancerous B cells and then delivers a drug specifically to those cells.